Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth

Area of Science:

• Oncology
• Cell Biology
• Biochemistry

Background:

• Ras mutations are prevalent in many cancers, particularly pancreatic cancer.
• Constitutively active Ras promotes tumorigenesis through downstream signaling pathways.
• Targeting Ras directly is challenging, necessitating research into its downstream effects.

Purpose of the Study:

• To investigate the role of mitochondrial dynamics in Ras-driven tumorigenesis.
• To identify specific molecular mechanisms linking Ras activation to mitochondrial changes.
• To evaluate mitochondrial fission as a potential therapeutic target.

Main Methods:

• Utilized cell culture models with oncogenic Ras expression or MAPK pathway activation.
• Assessed mitochondrial morphology and fragmentation.
• Employed knockdown of Dynamin-related protein 1 (Drp1) to inhibit mitochondrial fission.
• Investigated Erk2-mediated phosphorylation of Drp1.
• Analyzed human pancreatic cancer samples.
• Evaluated tumor growth in xenograft models.

Main Results:

• Oncogenic Ras or MAPK activation increases mitochondrial fragmentation.
• Knockdown of Drp1 inhibits Ras-driven tumor growth.
• Erk2 phosphorylates Drp1 at Serine 616, mediating mitochondrial fission.
• Increased Drp1 phosphorylation and mitochondrial fragmentation are observed in human pancreatic cancer.
• Inhibiting Drp1 phosphorylation blocks Ras-associated mitochondrial fission and xenograft tumor growth.

Conclusions:

• Mitochondrial fragmentation, driven by Erk2-mediated Drp1 phosphorylation, is a key process in Ras-driven tumorigenesis.
• Blocking this specific mitochondrial fission pathway effectively inhibits tumor growth.
• Mitochondrial fission represents a promising therapeutic target for cancers driven by Ras/MAPK signaling.